JP2016515536A5 - - Google Patents

Download PDF

Info

Publication number: JP2016515536A5
Authority: JP; Japan
Prior art keywords: phenyl; substituted; unsubstituted; ethoxycarbonylamino; methyl
Prior art date: 2014-03-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2016503448A

Other languages

English (en)

Japanese (ja)

Other versions

JP6482086B2 (ja

JP2016515536A (ja

Filing date

2014-03-17

Publication date

2017-04-20

2014-03-17 Application filed filed Critical

2014-03-17 Priority claimed from PCT/US2014/030712 external-priority patent/WO2014145873A2/en

2016-05-30 Publication of JP2016515536A publication Critical patent/JP2016515536A/ja

2017-04-20 Publication of JP2016515536A5 publication Critical patent/JP2016515536A5/ja

2019-03-13 Application granted granted Critical

2019-03-13 Publication of JP6482086B2 publication Critical patent/JP6482086B2/ja

Status Active legal-status Critical Current

2034-03-17 Anticipated expiration legal-status Critical

Links

150000001875 compounds Chemical class 0.000 claims 15
125000000217 alkyl group Chemical group 0.000 claims 13
125000002947 alkylene group Chemical group 0.000 claims 6
125000003709 fluoroalkyl group Chemical group 0.000 claims 6
125000001072 heteroaryl group Chemical group 0.000 claims 6
-1 R C is —F Chemical group 0.000 claims 5
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 5
125000003118 aryl group Chemical group 0.000 claims 5
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
229910052799 carbon Inorganic materials 0.000 claims 4
125000001309 chloro group Chemical group Cl* 0.000 claims 4
125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
125000002993 cycloalkylene group Chemical group 0.000 claims 3
FMNGLFKMWOZMJZ-MZNJEOGPSA-N (2r)-3-(4-bromophenyl)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]propanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=C(Br)C=C1 FMNGLFKMWOZMJZ-MZNJEOGPSA-N 0.000 claims 2
125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 2
125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 2
150000000022 5-membered heteroarenes Chemical class 0.000 claims 2
125000004432 carbon atom Chemical group C* 0.000 claims 2
125000000753 cycloalkyl group Chemical group 0.000 claims 2
230000001419 dependent effect Effects 0.000 claims 2
201000010099 disease Diseases 0.000 claims 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
239000003814 drug Substances 0.000 claims 2
229910052736 halogen Inorganic materials 0.000 claims 2
150000002367 halogens Chemical class 0.000 claims 2
125000000623 heterocyclic group Chemical group 0.000 claims 2
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
DNTASSMVWDKGEL-KBMIEXCESA-N (2r)-2-[[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]methylamino]-3-[4-(trifluoromethyl)phenyl]propanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C=CC=CC=1)C(O)=O)C1=CC=C(C(F)(F)F)C=C1 DNTASSMVWDKGEL-KBMIEXCESA-N 0.000 claims 1
DVQWHRUNKRFWKU-CJFMBICVSA-N (2r)-2-[[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]methylamino]-3-phenylpropanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 DVQWHRUNKRFWKU-CJFMBICVSA-N 0.000 claims 1
ITTQHEXJRGBDRV-MZNJEOGPSA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]-3-(2-fluorophenyl)propanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=CC=C1F ITTQHEXJRGBDRV-MZNJEOGPSA-N 0.000 claims 1
SQFCAGDNKYIPQF-VOIUYBSRSA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]-3-(3,4-difluorophenyl)propanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=C(F)C(F)=C1 SQFCAGDNKYIPQF-VOIUYBSRSA-N 0.000 claims 1
BIWJMEMDKAXHNL-MZNJEOGPSA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]-3-(4-fluorophenyl)propanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=C(F)C=C1 BIWJMEMDKAXHNL-MZNJEOGPSA-N 0.000 claims 1
FVGWGHOSJIRUFY-KBMIEXCESA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]-3-(4-methylphenyl)propanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=C(C)C=C1 FVGWGHOSJIRUFY-KBMIEXCESA-N 0.000 claims 1
JEACLEXWCNRNKN-HOYKHHGWSA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]-3-phenylpropanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=CC=C1 JEACLEXWCNRNKN-HOYKHHGWSA-N 0.000 claims 1
XCLWZCYDJNBLCW-IQGLISFBSA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]phenyl]methylamino]-3-[4-(trifluoromethyl)phenyl]propanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=C(C(F)(F)F)C=C1 XCLWZCYDJNBLCW-IQGLISFBSA-N 0.000 claims 1
FXGHIICVGOZMMB-OPAMFIHVSA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]phenyl]methylamino]-3-cyclopropylpropanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1CC1 FXGHIICVGOZMMB-OPAMFIHVSA-N 0.000 claims 1
WBYQMFJYFSEDBU-KBMIEXCESA-N (2r)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]phenyl]methylamino]-3-phenylpropanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=CC=C1 WBYQMFJYFSEDBU-KBMIEXCESA-N 0.000 claims 1
ARXHIRFXSXLYHD-KBMIEXCESA-N (2r)-3-(2-chlorophenyl)-2-[[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]methylamino]propanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1Cl ARXHIRFXSXLYHD-KBMIEXCESA-N 0.000 claims 1
ZAJATRVMUICHSW-MZNJEOGPSA-N (2r)-3-(2-chlorophenyl)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]benzoyl]amino]propanoic acid Chemical compound C([C@@H](NC(=O)C1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=CC=C1Cl ZAJATRVMUICHSW-MZNJEOGPSA-N 0.000 claims 1
XPFZMUSJNQAECK-IQGLISFBSA-N (2r)-3-(2-chlorophenyl)-2-[[4-[4-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]phenyl]methylamino]propanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C(=CC=CC=1)Cl)C(O)=O)C1=CC=CC=C1Cl XPFZMUSJNQAECK-IQGLISFBSA-N 0.000 claims 1
IMIXACYBJVVYOY-KBMIEXCESA-N (2r)-3-(2-fluorophenyl)-2-[[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]methylamino]propanoic acid Chemical compound C([C@@H](NCC1=CC=C(C=C1)C=1ON=C(C)C=1NC(=O)O[C@H](C)C=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1F IMIXACYBJVVYOY-KBMIEXCESA-N 0.000 claims 1
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
BYOMTTIAEXZFDJ-MRXNPFEDSA-N 1-[4-[4-[5-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-4-fluoropyrazol-1-yl]phenyl]-2-fluorophenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(F)C=NN1C(C=C1)=CC=C1C(C=C1F)=CC=C1C1(C(O)=O)CC1 BYOMTTIAEXZFDJ-MRXNPFEDSA-N 0.000 claims 1
XVNWTGXJZLFDKA-MRXNPFEDSA-N 1-[4-[4-[5-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-4-fluoropyrazol-1-yl]phenyl]-3-fluorophenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(F)C=NN1C(C=C1)=CC=C1C(C(=C1)F)=CC=C1C1(C(O)=O)CC1 XVNWTGXJZLFDKA-MRXNPFEDSA-N 0.000 claims 1
LGXDKSKWIVKEQA-GOSISDBHSA-N 1-[4-[4-[5-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-4-fluoropyrazol-1-yl]phenyl]-3-methylphenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(F)C=NN1C(C=C1)=CC=C1C(C(=C1)C)=CC=C1C1(C(O)=O)CC1 LGXDKSKWIVKEQA-GOSISDBHSA-N 0.000 claims 1
KGBNHXHOPVUASI-QGZVFWFLSA-N 1-[4-[4-[5-[[(1r)-1-(2-chlorophenyl)ethoxy]carbonylamino]-4-fluoropyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C(=CC=CC=1)Cl)C(=O)NC1=C(F)C=NN1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 KGBNHXHOPVUASI-QGZVFWFLSA-N 0.000 claims 1
NXDMYFBKUGPDMK-GOSISDBHSA-N 1-[4-[4-[5-[[(1r)-1-phenylethoxy]carbonylamino]-4-(trifluoromethyl)pyrazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC1=C(C(F)(F)F)C=NN1C(C=C1)=CC=C1C(C=C1)=CC=C1C1(C(O)=O)CC1 NXDMYFBKUGPDMK-GOSISDBHSA-N 0.000 claims 1
ZMBYEYYGLMMXFD-VGOKPJQXSA-N 2-[[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]methoxy]-3-phenylpropanoic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC=1C(C)=NOC=1C(C=C1)=CC=C1COC(C(O)=O)CC1=CC=CC=C1 ZMBYEYYGLMMXFD-VGOKPJQXSA-N 0.000 claims 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
BBDSWHRPUYCMKX-PLEWWHCXSA-N 3-cyclopropyl-2-[[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]methoxy]propanoic acid Chemical compound O([C@H](C)C=1C=CC=CC=1)C(=O)NC=1C(C)=NOC=1C(C=C1)=CC=C1COC(C(O)=O)CC1CC1 BBDSWHRPUYCMKX-PLEWWHCXSA-N 0.000 claims 1
125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
239000002253 acid Substances 0.000 claims 1
125000003545 alkoxy group Chemical group 0.000 claims 1
125000000732 arylene group Chemical group 0.000 claims 1
150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 1
125000004428 fluoroalkoxy group Chemical group 0.000 claims 1
125000004404 heteroalkyl group Chemical group 0.000 claims 1
125000005549 heteroarylene group Chemical group 0.000 claims 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
125000004433 nitrogen atom Chemical group N* 0.000 claims 1
125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 claims 1
239000000651 prodrug Substances 0.000 claims 1
229940002612 prodrug Drugs 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
125000001424 substituent group Chemical group 0.000 claims 1
125000003831 tetrazolyl group Chemical group 0.000 claims 1

JP2016503448A 2013-03-15 2014-03-17 疾患の治療に有用な複素環化合物 Active JP6482086B2 (ja)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201361801426P	2013-03-15	2013-03-15
US201361801231P	2013-03-15	2013-03-15
US61/801,426		2013-03-15
US61/801,231		2013-03-15
US201361827409P	2013-05-24	2013-05-24
US61/827,409		2013-05-24
PCT/US2014/030712 WO2014145873A2 (en)	2013-03-15	2014-03-17	Heterocyclic compounds useful in the treatment of disease

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2019020553A Division JP6843903B2 (ja)	2013-03-15	2019-02-07	疾患の治療に有用な複素環化合物

Publications (3)

Publication Number	Publication Date
JP2016515536A JP2016515536A (ja)	2016-05-30
JP2016515536A5 true JP2016515536A5 (2)	2017-04-20
JP6482086B2 JP6482086B2 (ja)	2019-03-13

Family

ID=51538557

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
JP2016503448A Active JP6482086B2 (ja)	2013-03-15	2014-03-17	疾患の治療に有用な複素環化合物
JP2019020553A Active JP6843903B2 (ja)	2013-03-15	2019-02-07	疾患の治療に有用な複素環化合物
JP2024059851A Active JP7754979B2 (ja)	2013-03-15	2024-04-03	疾患の治療に有用な複素環化合物
JP2025166007A Pending JP2026004456A (ja)	2013-03-15	2025-10-02	疾患の治療に有用な複素環化合物

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
JP2019020553A Active JP6843903B2 (ja)	2013-03-15	2019-02-07	疾患の治療に有用な複素環化合物
JP2024059851A Active JP7754979B2 (ja)	2013-03-15	2024-04-03	疾患の治療に有用な複素環化合物
JP2025166007A Pending JP2026004456A (ja)	2013-03-15	2025-10-02	疾患の治療に有用な複素環化合物

Country Status (15)

Country	Link
US (5)	US10000459B2 (2)
EP (1)	EP2988743B1 (2)
JP (4)	JP6482086B2 (2)
KR (1)	KR102090231B1 (2)
CN (3)	CN105142635B (2)
AU (3)	AU2014232383B2 (2)
BR (2)	BR112015023267B1 (2)
CA (1)	CA2906931C (2)
DK (1)	DK2988743T3 (2)
EA (1)	EA033923B1 (2)
ES (1)	ES2855173T3 (2)
MX (3)	MX382748B (2)
PT (1)	PT2988743T (2)
SG (3)	SG10201803833WA (2)
WO (1)	WO2014145873A2 (2)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2014145873A2 (en) *	2013-03-15	2014-09-18	Epigen Biosciences, Inc.	Heterocyclic compounds useful in the treatment of disease
EP3378491A4 (en) *	2015-11-20	2019-07-17	UBE Industries, Ltd.	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF NASH
KR102292989B1 (ko) *	2017-03-29	2021-08-26	재단법인 아산사회복지재단	S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
CN112041302B (zh) *	2017-12-19	2024-11-19	百时美施贵宝公司	作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸
US11447475B2 (en)	2017-12-19	2022-09-20	Bristol-Myers Squibb Company	Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
ES2898364T3 (es)	2017-12-19	2022-03-07	Bristol Myers Squibb Co	Acidos carbamoilciclohexílicos ligados a N triazol como antagonistas de LPA
US11261180B2 (en)	2017-12-19	2022-03-01	Bristol-Myers Squibb Company	Cyclohexyl acid isoxazole azoles as LPA antagonists
EP3728209B1 (en)	2017-12-19	2025-12-24	Bristol-Myers Squibb Company	Cyclohexyl acid isoxazole azines as lpa antagonists
EP3728216B1 (en) *	2017-12-19	2023-09-06	Bristol-Myers Squibb Company	Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
JP7299892B2 (ja) *	2017-12-19	2023-06-28	ブリストル－マイヤーズスクイブカンパニー	Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン
WO2019126084A1 (en) *	2017-12-19	2019-06-27	Bristol-Myers Squibb Company	Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
JP7212047B2 (ja) *	2017-12-19	2023-01-24	ブリストル－マイヤーズスクイブカンパニー	Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
US12522587B2 (en)	2018-05-04	2026-01-13	Remedy Plan, Inc.	Cancer treatments targeting cancer stem cells
EP3807254A4 (en) *	2018-06-18	2022-03-23	Epigen Biosciences, Inc.	HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES
ES2946657T3 (es)	2018-09-18	2023-07-24	Bristol Myers Squibb Co	Acidos ciclopentílicos como antagonistas de LPA
EP3853232B1 (en)	2018-09-18	2023-03-01	Bristol-Myers Squibb Company	Oxabicyclo acids as lpa antagonists
CA3121202A1 (en)	2018-11-30	2020-06-04	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
WO2020232247A1 (en)	2019-05-14	2020-11-19	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
US20240122934A1 (en) *	2019-10-16	2024-04-18	University Of South Florida	Compositions and methods of treatment for inhibiting capillary tube regression
EP4055008A1 (en)	2019-11-06	2022-09-14	Remedy Plan, Inc.	Cancer treatments targeting cancer stem cells
EP4058144A1 (en)	2019-11-15	2022-09-21	Gilead Sciences, Inc.	Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
TWI843503B (zh)	2020-06-03	2024-05-21	美商基利科學股份有限公司	Lpa受體拮抗劑及其用途
EP4161936A1 (en)	2020-06-03	2023-04-12	Gilead Sciences, Inc.	Lpa receptor antagonists and uses thereof
IL298999A (en)	2020-06-11	2023-02-01	Provention Bio Inc	Methods and compositions for the prevention of type 1 diabetes
WO2022006470A1 (en)	2020-07-01	2022-01-06	Vanderbilt University	Methods of treatment for a kidney disease
CA3185111A1 (en) *	2020-07-16	2022-01-20	Elisabetta Armani	Amido cyclohexane acid derivatives as lpa receptor inhibitors
WO2022034568A1 (en) *	2020-08-11	2022-02-17	Viva Star Biosciences Limited	Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists
WO2022240879A1 (en)	2021-05-11	2022-11-17	Gilead Sciences, Inc.	Lpa receptor antagonists and uses thereof
KR20240007233A (ko)	2021-05-13	2024-01-16	길리애드 사이언시즈, 인코포레이티드	Lpa 수용체 길항제 및 이의 용도
JP2024520444A (ja)	2021-05-24	2024-05-24	プロヴェンション・バイオ・インコーポレイテッド	１型糖尿病を治療するための方法
WO2023107938A1 (en)	2021-12-08	2023-06-15	Gilead Sciences, Inc.	Lpa receptor antagonists and uses thereof
TW202342017A (zh)	2022-02-25	2023-11-01	美商洛子峰生物有限公司	用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物
EP4622713A1 (en) *	2022-11-24	2025-10-01	Lhotse Bio, Inc.	Compounds and compositions for treating conditions associated with lpa receptor activity

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO2308B1 (en)	1999-05-31	2005-09-12	اف. هوفمان- لاروش أيه جي‏	Derivatives of phenylpyrmidine
PT1258484E (pt) *	2000-02-18	2009-04-03	Kyowa Hakko Kirin Co Ltd	Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos
WO2002062389A1 (en)	2001-02-08	2002-08-15	Ono Pharmaceutical Co., Ltd.	Remedies for urinary diseases comprising lpa receptor controlling agents
US20060148858A1 (en)	2002-05-24	2006-07-06	Tsuyoshi Maekawa	1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity
TW200508215A (en)	2003-06-11	2005-03-01	Sankyo Co	Cyclic tertiary amine compounds
JP4692281B2 (ja)	2003-08-05	2011-06-01	味の素株式会社	新規アゾール化合物
EP1682494A4 (en)	2003-10-30	2006-11-08	Merck & Co Inc	ARALKYLAMINES AS MODULATORS OF CANNABINOID RECEPTORS
ES2314633T3 (es)	2004-03-26	2009-03-16	F. Hoffmann-La Roche Ag	Tetrahidrocarbazoles y derivados.
EP1732541A4 (en)	2004-04-07	2008-03-05	Takeda Pharmaceutical	CYCLIC COMPOUNDS
BRPI0612287A8 (pt) *	2005-06-27	2019-01-22	Exelixis Inc	composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
TW200803740A (en) *	2005-12-16	2008-01-16	Du Pont	5-aryl isoxazolines for controlling invertebrate pests
EP2096111A1 (en)	2006-11-20	2009-09-02	Japan Tobacco Inc.	Pyrazoles and use thereof as drugs
WO2009051245A1 (ja)	2007-10-18	2009-04-23	Kumiai Chemical Industry Co., Ltd.	３－アルコキシ－１－フェニルピラゾ－ル誘導体及び有害生物防除剤
WO2010004507A1 (en)	2008-07-07	2010-01-14	Actelion Pharmaceuticals Ltd	Thiazolidine compounds as orexin receptor antagonists
GB2466121B (en)	2008-12-15	2010-12-08	Amira Pharmaceuticals Inc	Antagonists of lysophosphatidic acid receptors
GB2470833B (en)	2009-06-03	2011-06-01	Amira Pharmaceuticals Inc	Polycyclic antagonists of lysophosphatidic acid receptors
CN102574822A (zh)	2009-08-04	2012-07-11	阿米拉制药公司	作为溶血磷脂酸受体拮抗剂的化合物
JP4683154B2 (ja)	2009-08-12	2011-05-11	横浜ゴム株式会社	冷媒移送用ホース
GB2474748B (en)	2009-10-01	2011-10-12	Amira Pharmaceuticals Inc	Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en)	2009-10-01	2011-12-21	Amira Pharmaceuticals Inc	Compounds as Lysophosphatidic acid receptor antagonists
WO2011159632A1 (en)	2010-06-15	2011-12-22	Amira Pharmaceuticals, Inc.	Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
WO2011159635A1 (en)	2010-06-15	2011-12-22	Amira Pharmaceuticals, Inc.	Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
WO2011159633A1 (en)	2010-06-15	2011-12-22	Amira Pharmaceuticals, Inc.	Inhalable formulations of lysophosphatdic acid receptor antagonists
US20120031985A1 (en)	2010-08-09	2012-02-09	Terry Lien Do	Fault tolerant appliance
KR20130126659A (ko) *	2010-12-07	2013-11-20	아미라 파마슈티칼스 인코포레이티드	리소포스파티드산 수용체 길항제 및 섬유증 치료에서의 그의 용도
DK2648726T3 (da)	2010-12-07	2018-07-16	Amira Pharmaceuticals Inc	Polycyklisk lpa1-antagonist og anvendelser deraf
US8785442B2 (en)	2011-01-30	2014-07-22	Curegenix, Inc.	Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
WO2012138648A1 (en) *	2011-04-06	2012-10-11	Irm Llc	Compositions and methods for modulating lpa receptors
JP2014525932A (ja) *	2011-08-15	2014-10-02	インターミューン，インコーポレイテッド	リゾホスファチド酸レセプターアンタゴニスト
WO2013070879A1 (en)	2011-11-10	2013-05-16	Bristol-Myers Squibb Company	Methods for treating spinal cord injury with lpa receptor antagonists
US20140329871A1 (en)	2011-12-04	2014-11-06	Angion Biomedica Corp.	Small molecule anti-fibrotic compounds and uses thereof
US9499538B2 (en)	2012-03-20	2016-11-22	Seragon Pharmaceuticals, Inc.	Estrogen receptor modulators and uses thereof
SG11201407229UA (en)	2012-06-20	2014-12-30	Hoffmann La Roche	Substituted pyrazole compounds as lpar antagonists
JP2015520202A (ja)	2012-06-20	2015-07-16	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｌｐａｒ拮抗薬としてのｎ−アルキルトリアゾール化合物
IN2014DN09352A (2)	2012-06-20	2015-07-17	Hoffmann La Roche
KR102189166B1 (ko)	2012-12-28	2020-12-09	우베 고산 가부시키가이샤	할로겐 치환 헤테로환 화합물
US20140213538A1 (en)	2013-01-15	2014-07-31	Intermune, Inc.	Lysophosphatidic acid receptor antagonists
WO2014145873A2 (en)	2013-03-15	2014-09-18	Epigen Biosciences, Inc.	Heterocyclic compounds useful in the treatment of disease
US9987381B2 (en)	2013-10-31	2018-06-05	Bristol-Myers Squibb Company	Radioligands for imaging the LPA-1 receptor
RU2689315C2 (ru)	2014-06-27	2019-05-27	Убе Индастриз, Лтд.	Соль гетероциклического соединения, замещенного галогеном
EP3807254A4 (en)	2018-06-18	2022-03-23	Epigen Biosciences, Inc.	HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES

2014
- 2014-03-17 WO PCT/US2014/030712 patent/WO2014145873A2/en not_active Ceased
- 2014-03-17 MX MX2015013303A patent/MX382748B/es unknown
- 2014-03-17 CN CN201480015333.XA patent/CN105142635B/zh active Active
- 2014-03-17 AU AU2014232383A patent/AU2014232383B2/en active Active
- 2014-03-17 ES ES14762555T patent/ES2855173T3/es active Active
- 2014-03-17 SG SG10201803833WA patent/SG10201803833WA/en unknown
- 2014-03-17 DK DK14762555.2T patent/DK2988743T3/da active
- 2014-03-17 PT PT147625552T patent/PT2988743T/pt unknown
- 2014-03-17 JP JP2016503448A patent/JP6482086B2/ja active Active
- 2014-03-17 US US14/776,954 patent/US10000459B2/en active Active
- 2014-03-17 CA CA2906931A patent/CA2906931C/en active Active
- 2014-03-17 EA EA201591607A patent/EA033923B1/ru unknown
- 2014-03-17 KR KR1020157028061A patent/KR102090231B1/ko active Active
- 2014-03-17 BR BR112015023267-1A patent/BR112015023267B1/pt active IP Right Grant
- 2014-03-17 EP EP14762555.2A patent/EP2988743B1/en active Active
- 2014-03-17 SG SG11201507459YA patent/SG11201507459YA/en unknown
2018
- 2018-06-05 US US16/000,283 patent/US10570103B2/en active Active
- 2018-06-18 US US16/010,755 patent/US10526298B2/en active Active
2019
- 2019-02-07 JP JP2019020553A patent/JP6843903B2/ja active Active
- 2019-04-17 AU AU2019202731A patent/AU2019202731B2/en active Active
- 2019-06-18 CN CN201980047732.7A patent/CN112424174B/zh active Active
- 2019-06-18 AU AU2019288275A patent/AU2019288275B2/en active Active
- 2019-06-18 SG SG11202012656WA patent/SG11202012656WA/en unknown
- 2019-06-18 CN CN202410150847.1A patent/CN118290357A/zh active Pending
- 2019-06-18 US US18/015,289 patent/US20230286928A1/en active Pending
- 2019-06-18 MX MX2020014300A patent/MX2020014300A/es unknown
- 2019-06-18 BR BR112020025927-6A patent/BR112020025927A2/pt unknown
2020
- 2020-02-07 US US16/784,486 patent/US11427552B2/en active Active
- 2020-12-18 MX MX2024011839A patent/MX2024011839A/es unknown
2024
- 2024-04-03 JP JP2024059851A patent/JP7754979B2/ja active Active
2025
- 2025-10-02 JP JP2025166007A patent/JP2026004456A/ja active Pending

Publication	Publication Date	Title
JP2016515536A5 (2)	2017-04-20
JP2019034943A5 (2)	2019-06-06
JP2018510139A5 (2)	2019-03-14
JP2009541340A5 (2)	2010-08-05
JP2011502958A5 (2)	2011-06-30
JP2016509591A5 (2)	2016-07-21
JP2019514874A5 (2)	2020-05-28
JP2017522277A5 (2)	2018-07-19
JP2009543795A5 (2)	2010-08-26
RU2018101077A (ru)	2019-07-15	Регуляторы nrf2
JP2010513397A5 (2)	2010-08-19
JP2012524111A5 (2)	2013-04-25
JP2015531774A5 (2)	2015-12-17
JP2010524932A5 (2)	2011-06-16
JP2010526025A5 (2)	2011-03-10
JP2014530900A5 (2)	2015-12-03
JP2009263394A5 (2)	2011-07-21
RU2018112749A (ru)	2019-10-24	Модуляторы индоламин-2,3-диоксигеназы
JP2016512844A5 (2)	2017-09-07
JP2011523647A5 (2)	2012-07-19
JP2009530399A5 (2)	2010-05-13
JP2010513435A5 (2)	2011-02-10
JP2012255002A5 (2)	2013-07-18
JP2017505293A5 (2)	2017-12-28
RU2011147203A (ru)	2013-05-27	Гетероароматические и ароматические пиперазинилазетидиниламиды в качестве ингибиторов моноацилглицеринлипазы